MOMIPP |
| Catalog No.GC66013 |
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1363421-46-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2].
MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1].
In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization[1].
MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2].
Western Blot Analysis[2]
| Cell Line: | U251 cells |
| Concentration: | 10 μM |
| Incubation Time: | 4 h or 24 h |
| Result: | Activated the JNK stress kinase pathway. |
MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2].
| Animal Model: | Athymic CrTac:NCR-Foxn1 |
| Dosage: | 80 mg/kg |
| Administration: | i.p.; once daily; for 15 consecutive days |
| Result: | Suppressed progression of intracerebral glioblastoma xenografts. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *